Eli Lilly and Company (LLY)
After hours:
| Previous close | 821.19 |
| Open | 811.87 |
| Bid | 803.73 x 1100 |
| Ask | 804.61 x 1100 |
| Day's range | 801.30 - 821.99 |
| 52-week range | 446.89 - 966.10 |
| Volume | |
| Avg. volume | 2,944,966 |
| Market cap | 724.484B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 117.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.20 (0.63%) |
| Ex-dividend date | 15 Aug 2024 |
| 1y target est | N/A |
- PR Newswire
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
- PR Newswire
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
- PR Newswire
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.1, 2 Once-monthly Kisunla is the first and only amyloid plaque-targeting therapy with evidence to suppo
